Inventor
MILSTEIN STUART
US92 patents
⚠️ This page may combine multiple inventors who share the name “MILSTEIN STUART”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
ALNYLAM PHARMACEUTICALS INC
38 patentsUS10337010B2Jul 2, 2019
Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC17 citations98
US9771591B2Sep 26, 2017
Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC22 citations98
US9322018B2Apr 26, 2016
Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC36 citations98
US10612027B2Apr 7, 2020
Modified double-stranded RNA agents
ALNYLAM PHARMACEUTICALS INC26 citations97
US10233448B2Mar 19, 2019
Modified double-stranded RNA agents
ALNYLAM PHARMACEUTICALS INC37 citations97
US11525138B2Dec 13, 2022
Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC7 citations94
US11332743B2May 17, 2022
Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC6 citations94
US11306315B2Apr 19, 2022
Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC6 citations94
US11306316B2Apr 19, 2022
Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC6 citations94
US11306314B2Apr 19, 2022
Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC6 citations94
US10557139B2Feb 11, 2020
Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC15 citations94
US10550390B2Feb 4, 2020
Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC15 citations94
US10612024B2Apr 7, 2020
Modified double-stranded RNA agents
ALNYLAM PHARMACEUTICALS INC15 citations93
US11130953B2Sep 28, 2021
Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC8 citations92
US9234196B2Jan 12, 2016
Compositions and methods for inhibiting expression of transthyretin
ALNYLAM PHARMACEUTICALS INC18 citations92
US11866709B2Jan 9, 2024
Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC3 citations86
US11401517B2Aug 2, 2022
Modified double-stranded RNA agents
ALNYLAM PHARMACEUTICALS INC6 citations85
US11840692B2Dec 12, 2023
Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC3 citations84
US11834662B2Dec 5, 2023
Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC3 citations84
US11504391B1Nov 22, 2022
Modified RNA agents with reduced off-target effect
ALNYLAM PHARMACEUTICALS INC18 citations84
US11142766B2Oct 12, 2021
Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC4 citations84
US11034958B2Jun 15, 2021
Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC7 citations84
US10934545B2Mar 2, 2021
Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC6 citations84
US10513703B2Dec 24, 2019
Hepatitis B virus (HBV) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC6 citations84
US10407679B2Sep 10, 2019
Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC5 citations84
US10238749B2Mar 26, 2019
Angiotensinogen (AGT) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC12 citations84
US10125369B2Nov 13, 2018
PCSK9 iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC9 citations84
US9376680B2Jun 28, 2016
Serpinc1 iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC7 citations84
US10995336B2May 4, 2021
Serpina1 iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC8 citations83
US10246713B2Apr 2, 2019
TMPRSS6 iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC6 citations83
US10240152B2Mar 26, 2019
Compositions and methods for inhibiting expression of transthyretin
ALNYLAM PHARMACEUTICALS INC6 citations83
US12467051B2Nov 11, 2025
Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC0 citations73
US11492623B2Nov 8, 2022
Hepatitis B virus (HBV) dsRNA agent compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC4 citations73
US11419942B2Aug 23, 2022
Angiotensinogen (AGT) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC2 citations73
US11408001B1Aug 9, 2022
Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC1 citations73
US11060091B2Jul 13, 2021
Hepatitis B virus (HBV) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC2 citations73
US10814007B2Oct 27, 2020
Angiotensinogen (AGT) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC3 citations73
US9970006B2May 15, 2018
Compositions and methods for inhibition of expression of apolipoprotein C-III (APOC3) genes
ALNYLAM PHARMACEUTICALS INC4 citations73
SAH DINAH WEN-YEE
2 patentsFITZGERALD KEVIN
2 patentsALNYLAM PHARMACEUTICALS
1 patentARROWHEAD PHARMACEUTICALS INC
1 patentARROWHEAD RES CORP
1 patentBETTENCOURT BRIAN
1 patentHINKLE GREGORY
1 patentTOUDJARSKA IVANKA
1 patentCHEN JINYUN
1 patentARROWHEAD RES CORPORATION
1 patentShowing the top 50 of 92 patents by PatentIndex Score.